Strategic Acquisition 360biolabs is now part of BioAgilytix, indicating a consolidated global contract research footprint with enhanced capabilities across large molecule drug development. This presents cross-sell opportunities to BioAgilytix’s broader client base seeking Australian/ANZ and European partnerships.

Full-Service Bioanalysis As Australia’s most comprehensive bioanalytical and specialty laboratory offering PK, PD, LC/MS, flow cytometry, biomarkers and molecular assays, there is potential to upsell integrated testing programs for Phase I-III trials and expand into additional assay platforms for existing customers.

Global Reach With laboratories in Melbourne, Brisbane, the United States and Europe, there is a strong case for multi-region studies and centralized sample management, enabling sales conversations around GLP/GCP/ISO17025 compliance and harmonized ICH/FDA/EMA-aligned methods across sites.

Quality and Compliance Emphasis on high-quality standards and robust quality systems positions 360biolabs to target sponsors prioritizing stringent regulatory compliance, real-time method transfer, and validated assays, suggesting opportunities for increased outsourcing of validated method development and transfer services.

Growth Potential Revenue range indicates growing mid-market presence; combined with recent acquisitions, there is room to engage mid-to-large biotech and pharma clients seeking regional CRO partnerships for large molecule programs, biomarker-driven studies, and centralized laboratory services.